Page last updated: 2024-11-07

phenylalanyl-glycyl-glycine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

phenylalanyl-glycyl-glycine: RN given refers to (L-PHe)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Phe-Gly-Gly : A tripeptide composed of one L-phenylalanine and two glycine residues joined in sequence. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID152644
CHEBI ID74714
SCHEMBL ID1330246
MeSH IDM0128901

Synonyms (24)

Synonym
23576-42-3
phenylalanyl-glycyl-glycine
phe-gly-gly
2-[[2-[[(2s)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetic acid
glycine, n-(n-l-phenylalanylglycyl)-
SCHEMBL1330246
AKOS010407261
n-(n-l-phenylalanylglycyl)-glycine
l-phenylalanylglycylglycine
phenylalanylglycylglycine
l-phe-gly-gly
CHEBI:74714
(s)-2-(2-(2-amino-3-phenylpropanamido)acetamido)acetic acid
DTXSID00178213
2-{2-[(2s)-2-amino-3-phenylpropanamido]acetamido}acetic acid
AS-60337
D77702
mfcd00037785
CS-W010061
l-phenylalanyl-glycyl-glycine
Q27144853
glycine, l-phenylalanylglycyl-
(s)-2-(2-(2-amino-3-phenylpropanamido)acetamido)aceticacid
HY-W009345
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
tripeptideAny oligopeptide that consists of three amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (14.29)18.7374
1990's1 (7.14)18.2507
2000's5 (35.71)29.6817
2010's6 (42.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.34 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index5.05 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]